

Date: September 25, 2024

Ref. No.: KDL/SE/083/2024-25

<b>To,</b> <b>BSE Limited</b> <b>Corporate Relationship Department</b> 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 <b>Scrip Code:</b> 543328	<b>To,</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 <b>NSE Symbol:</b> KRSNAA
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for acquisition of 23.53% of stake in equity shares of Apulki Healthcare Private Limited.**

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the Board of Directors of Krsnaa Diagnostics Limited (“Krsnaa”) at its meeting held today i.e. September 25, 2024 inter alia approved the investment subject to fulfillment of certain conditions precedent in the Equity Share Capital of Apulki Healthcare Private Limited (“hereinafter referred as Apulki”).

The Company shall acquire 23.53% of the total paid up capital of Apulki.

The details required under Regulation 30 of SEBI LODR Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure I.

The Board Meeting commenced at 16:30 Hrs. (IST) and concluded at 19:00 (IST).

You are requested to take the above information on your record.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose  
Company Secretary and Compliance Officer

**Annexure-1**

Sr. No.	Particulars							
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Apulki Healthcare Private Limited (“Investee Company”).</p> <table border="1"> <tr> <td>Authorized Capital</td> <td>1,00,000</td> </tr> <tr> <td>Paid Up Capital</td> <td>1,00,000</td> </tr> <tr> <td>Turnover</td> <td>-</td> </tr> </table>	Authorized Capital	1,00,000	Paid Up Capital	1,00,000	Turnover	-
Authorized Capital	1,00,000							
Paid Up Capital	1,00,000							
Turnover	-							
2.	Whether the acquisition would fall with related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No, the transaction will not fall within the related party transaction and none of the promoter/promoter group/group companies are interested in the entity with whom the agreements are executed.						
3.	Industry to which the entity being acquired belongs	The Investee Company is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology.						
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Investee Company is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology in the public private partnership mode having entered into agreements for a tenure of 30 years. Krsnaa gets exclusive partnership of operating and maintaining diagnostic services of the Investee Company’s hospitals.						
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None						
6.	Indicative time period for completion of the acquisition	Within 3 Months						
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration						
8.	Cost of acquisition and/or the price at which the shares are acquired	Acquisition of the shares of the Investee Company will be done at a mutually agreed enterprise valuation. The said enterprise valuation has not been disclosed herein due to reasons of confidentiality.						
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of equity shares of 23.53% will be done by acquiring / subscribing shares of the Investee Company.						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>The Investee Company is a start-up engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology, primarily under public-private partnership.</p> <p>Date of Incorporation: June 13, 2022.</p> <p>Turnover: Nil</p>						

**Krsnaa Diagnostics Ltd.**

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,  
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)  
020 27402400 | info@krsnaa.in

